following a full submission assessed under the end of life and orphan equivalent medicine process:
epcoritamab (Tepkinly®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
In a phase I/II open-label study, 62% of patients treated with epcoritamab who had R/R DLBCL after two or more lines of systemic therapy achieved objective response.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting
Medicine details
- Medicine name:
- epcoritamab (Tepkinly)
- SMC ID:
- SMC2632
- Indication:
As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 June 2024